The effectiveness and safety of direct oral anticoagulants (DOAC) compared with warfarin
remains uncertain in obese patients. We assessed the comparative effectiveness and safety …

Objective: To review literature on the use of direct-acting oral anticoagulants (DOACs) in
patients with high body weight (BW) and/or high body mass index (BMI) and to make …

Background: Real-world data show limited utilization of direct oral anticoagulants (DO-ACs)
in obese patients (body mass index [BMI]≥ 30 kg/m2) due to concerns regarding their …

Background: Obesity is a well-known risk factor for venous thromboembolism (VTE),
however, obese patients are under-represented in clinical trials (1; 2). Four direct oral …

Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …

Introduction: There is limited efficacy and safety data for direct oral anticoagulants (DOACs)
in patients with obesity, and it has been suggested to avoid DOACs in this patient …

Background: Use of direct-acting oral anticoagulants (DOACs) in morbidly obese (BMI> 40
kg/m 2) patients for venous thromboembolism (VTE) treatment is not fully understood …

Abstract Purpose of Review The purpose of this review is to examine the safety and
effectiveness of direct oral anticoagulants and provide recommendations for the treatment of …

Background: Many publications have compared various outcomes defining safety and
efficacy of DOACs across different BMI ranges. Our meta-analysis compares warfarin and …

Background There is scarce evidence on the effectiveness and safety of recommended-
dose direct acting oral anticoagulants (DOACs) in obese patients with venous …